Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers.
Fecha de publicación:
Fecha Ahead of Print:
Autores de IIS La Fe
Participantes ajenos a IIS La Fe
- Novelli, Silvana
- Bento, Leyre
- Garcia, Irene
- Prieto, Laura
- Lopez, Lucia
- Gutierrez, Gonzalo
- Hernani, Rafael
- Perez, Ariadna
- Esquirol, Albert
- Solano, Carlos
- Bastos, Mariana
- Dorado, Nieves
- Rodriguez, Nancy
- Rodriguez, Guillermo
- Herrera, Pilar
- Luna, Alejandro
- Parody, Rocio
- Martin, Carmen
- Garcia, Estefania
- Lopez, Oriana
- Heras, Inmaculada
- Zanabili, Joud
- Moraleda, Jose M
- Yanez, Lucrecia
- Gutierrez, Antonio
- Zudaire, Teresa
- Cordoba, Raul
- Varela, Rosario
- Ferra, Christelle
- Martinez, Joaquin
- Martinez, Carmen
- Gonzalez-Barca, Eva
- Martino, Rodrigo
- Caballero, Dolores
Grupos
Abstract
Despite advances in understanding the biology of mature T and natural killer (NK)/T cell neoplasia, current therapies, even the most innovative ones, are still far from ensuring its cure. The only treatment to date that has been shown to control aggressive T cell neoplasms in the long term is allogeneic stem cell transplantation (alloSCT). We aim to report the results of alloSCT for advanced mature T and NK/T neoplasias performed in centers from our national GELTAMO/GETH (Grupo Espanol de Linfoma y Trasplante de Medula Osea/Grupo Espanol de Trasplante Hematopoyetico y Terapia Celular) over the past 25 years. As a secondary objective, we analyzed the results of alloSCT from haploidentical donors. We performed a retrospective analysis of all patients who received an alloSCT in Spanish centers (n = 201) from September 1995 to August 2018. The 2-year overall survival (OS) and disease-free survival (DFS) were 65.5% and 58.2%, respectively. The univariate for OS and DFS showed statistically different hazard ratios for conditioning intensity, response pre-alloSCT, comorbidity index, donor/receptor cytomegalovirus status and Eastern Cooperative Oncology Group (ECOG) pre-alloSCT, but only a better ECOG pre-alloSCT remained significant in the multivariate analysis. There was an increased incidence of relapse in those patients who did not develop chronic graft-versus-host disease (GVHD) and an increased risk of death in those developing moderate to severe acute GVHD. The 1-year nonrelapse mortality was 21.9% and was mainly due to GVHD (30%) and bacterial infections (17%). When comparing unrelated donors with haploidentical donors, we found similar results in terms of OS and DFS. There was, however, a reduction of acute GVHD in the haploidentical group (P = .04) and trend to a reduction of chronic GVHD. In conclusion, alloSCT is the only curative option for most aggressive T cell neoplasias. Haploidentical donors offer similar results to related donors in terms of survival with a reduction of acute GVHD. (C) 2021 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc. All rights reserved.
Datos de la publicación
- ISSN/ISSNe:
- 2666-6375, 2666-6367
- Tipo:
- Article
- Páginas:
- 4931-4938
- PubMed:
- 33857447
Transplantation and Cellular Therapy ELSEVIER SCIENCE INC
Citas Recibidas en Web of Science: 9
Documentos
- No hay documentos
Filiaciones
Keywords
- Allogeneic stem cell transplantation; Haploidentical; T cell lymphoma
Campos de Estudio
Cita
Novelli S,Bento L,Garcia I,Prieto L,Lopez L,Gutierrez G,Hernani R,Perez A,Esquirol A,Solano C,Bastos M,Dorado N,Rodriguez N,Rodriguez G,PINANA JL,MONTORO J,Herrera P,Luna A,Parody R,Martin C,Garcia E,Lopez O,Heras I,Zanabili J,Moraleda JM,Yanez L,Gutierrez A,Zudaire T,Cordoba R,Varela R,Ferra C,Martinez J,Martinez C,Gonzalez E,Martino R,Caballero D. Allogeneic Stem Cell Transplantation in Mature T Cell and Natural Killer/T Neoplasias: A Registry Study from Spanish GETH/GELTAMO Centers. Transplant. Cell. Ther. 2021. 27. (6):p. 4931-4938.
Portal de investigación